LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 136

Search options

  1. Book: Multidisciplinary care of lung cancer patients / 2

    Elias, Anthony

    (Hematology, oncology clinics of North America ; 11,3)

    1997  

    Author's details Anthony Elias, guest ed
    Series title Hematology, oncology clinics of North America ; 11,3
    Multidisciplinary care of lung cancer patients
    Collection Multidisciplinary care of lung cancer patients
    Language English
    Size XI S., S. 387 - 546 : Ill., graph. Darst.
    Publisher Saunders
    Publishing place Philadelphia u.a.
    Publishing country United States
    Document type Book
    HBZ-ID HT007596343
    Database Catalogue ZB MED Medicine, Health

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    Se 1077 -11,3- verfügbar in Königswinter Königswinter

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Book: Multidisciplinary care of lung cancer patients / 1

    Elias, Anthony

    (Multiple myeloma ; 2 ; Hematology, oncology clinics of North America ; 11,2)

    1997  

    Author's details Anthony Elias, guest ed
    Series title Multiple myeloma ; 2
    Hematology, oncology clinics of North America ; 11,2
    Multidisciplinary care of lung cancer patients
    Collection Multidisciplinary care of lung cancer patients
    Language English
    Size XV S., S. 177 - 386 : Ill., graph. Darst.
    Publisher Saunders
    Publishing place Philadelphia u.a.
    Publishing country United States
    Document type Book
    HBZ-ID HT007545081
    Database Catalogue ZB MED Medicine, Health

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    Se 1077 -11,2- verfügbar in Königswinter Königswinter

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: Congenital Methemoglobinemia and Unstable Hemoglobin Variant in a Child With Cyanosis.

    Alsabri, Mohammed / Viswanathan, Kusum / Elias, Anthony / Peichev, Mario

    Cureus

    2021  Volume 13, Issue 7, Page(s) e16081

    Abstract: Methemoglobinemia (Meth) is a rare hemoglobin (Hb) disorder with distinguished clinical features and complex pathophysiology. We present a three-year-old female who was diagnosed with congenital methemoglobinemia when she presented with peri-oral ... ...

    Abstract Methemoglobinemia (Meth) is a rare hemoglobin (Hb) disorder with distinguished clinical features and complex pathophysiology. We present a three-year-old female who was diagnosed with congenital methemoglobinemia when she presented with peri-oral cyanosis and profound oxygen desaturation in the 20-30% range. This patient also had elevated deoxyhemoglobin (HHb) not explained by methemoglobinemia alone; the low pulse oximetry (SpO
    Language English
    Publishing date 2021-07-01
    Publishing country United States
    Document type Case Reports
    ZDB-ID 2747273-5
    ISSN 2168-8184
    ISSN 2168-8184
    DOI 10.7759/cureus.16081
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article: Management of Small T1a/b N0 Breast Cancers.

    Elias, Anthony D

    American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

    2013  , Page(s) 10–19

    Abstract: T1ab N0 breast cancer generally has excellent prognosis. Adverse prognostic factors include HER2+ disease, ER-negative disease, high-grade histology, T1b, and young age of patient. These patients are largely excluded from most trials, and to date, no ... ...

    Abstract T1ab N0 breast cancer generally has excellent prognosis. Adverse prognostic factors include HER2+ disease, ER-negative disease, high-grade histology, T1b, and young age of patient. These patients are largely excluded from most trials, and to date, no prospective studies for this group yet reported. Treatment guidelines are vague and treatment inconsistent. As yet, in the HER2+ population, little experience with targeted therapy has been reported. Prospective trials are needed.
    Language English
    Publishing date 2013-11-19
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2431126-1
    ISSN 1548-8756 ; 1548-8748
    ISSN (online) 1548-8756
    ISSN 1548-8748
    DOI 10.14694/EdBook_AM.2012.32.10
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Gauge against the machine: revisiting quality for multi-targeted serology platforms.

    Elias, Anthony / Tilbrook, Lynelle / Gray, Timothy / Varadhan, Hemalatha / George, C R Robert

    Pathology

    2022  

    Abstract: Diagnosis of infections of public health significance, such as leptospirosis, often present challenges for laboratories. To counter common challenges and ensure quality driven health responses, rigorous validation and verification processes are required. ...

    Abstract Diagnosis of infections of public health significance, such as leptospirosis, often present challenges for laboratories. To counter common challenges and ensure quality driven health responses, rigorous validation and verification processes are required. Despite such rigor, however, can one be certain laboratory reports are truly reflective of infection, given the risk of rare, but potentially very significant quality oversights? Here we present a real-world scenario where diagnosis of leptospirosis cases was compromised over a 6-year period despite quality measures suggesting a well performing serological assay. A subsequent investigation revealed this was attributed to the programming of an automated microtitration plate analyser, evading detection by both quality control and external quality assurance processes. The quality oversight provides insight into potential limitations in quality processes in multi-targeted serological platforms.
    Language English
    Publishing date 2022-11-22
    Publishing country England
    Document type Journal Article
    ZDB-ID 7085-3
    ISSN 1465-3931 ; 0031-3025
    ISSN (online) 1465-3931
    ISSN 0031-3025
    DOI 10.1016/j.pathol.2022.10.001
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 723: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Triple-negative breast cancer: a short review.

    Elias, Anthony D

    American journal of clinical oncology

    2010  Volume 33, Issue 6, Page(s) 637–645

    Abstract: This review describes the pathology, prognosis, current treatment options, and future directions for the management of patients with triple-negative breast cancer. "Triple-negative" tumors lack expression of estrogen and progesterone receptors, and HER2. ...

    Abstract This review describes the pathology, prognosis, current treatment options, and future directions for the management of patients with triple-negative breast cancer. "Triple-negative" tumors lack expression of estrogen and progesterone receptors, and HER2. The subtype comprises some 15% of all breast cancers, with tumors of a typically larger size and higher grade. Clinically, triple-negative breast cancer has a relatively high rate of recurrence and distant metastasis, and poor overall survival. The standard of care is chemotherapy, although recent research suggests a sound rationale for the use of targeted agents with antitumor and/or antiangiogenic activity such as receptor tyrosine kinase inhibitors.
    MeSH term(s) Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Biomarkers, Tumor/analysis ; Breast Neoplasms/drug therapy ; Breast Neoplasms/metabolism ; Breast Neoplasms/mortality ; Breast Neoplasms/pathology ; Disease-Free Survival ; Female ; Humans ; Middle Aged ; Neoplasm Recurrence, Local/mortality ; Neoplasm Recurrence, Local/pathology ; Neoplasm Recurrence, Local/physiopathology ; Neoplasm Staging ; Neoplasms, Hormone-Dependent/drug therapy ; Neoplasms, Hormone-Dependent/metabolism ; Neoplasms, Hormone-Dependent/mortality ; Neoplasms, Hormone-Dependent/pathology ; Prognosis ; Receptor, ErbB-2/metabolism ; Receptors, Estrogen/metabolism ; Receptors, Progesterone/metabolism ; Risk Assessment ; Survival Analysis ; Treatment Outcome
    Chemical Substances Biomarkers, Tumor ; Receptors, Estrogen ; Receptors, Progesterone ; Receptor, ErbB-2 (EC 2.7.10.1)
    Language English
    Publishing date 2010-12
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 604536-4
    ISSN 1537-453X ; 0277-3732
    ISSN (online) 1537-453X
    ISSN 0277-3732
    DOI 10.1097/COC.0b013e3181b8afcf
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1557: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: NCCN Guidelines Updates: Breast Cancer.

    Giordano, Sharon H / Elias, Anthony D / Gradishar, William J

    Journal of the National Comprehensive Cancer Network : JNCCN

    2018  Volume 16, Issue 5S, Page(s) 605–610

    Abstract: The emergence of CDK4/6 inhibitors has changed the treatment algorithm for advanced/metastatic estrogen receptor-positive breast cancer. In pivotal trials of palbociclib, ribociclib, and abemaciclib, doubling in progression-free survival has been seen. ... ...

    Abstract The emergence of CDK4/6 inhibitors has changed the treatment algorithm for advanced/metastatic estrogen receptor-positive breast cancer. In pivotal trials of palbociclib, ribociclib, and abemaciclib, doubling in progression-free survival has been seen. All 3 agents in this class are now included in the NCCN Guidelines for Breast Cancer, and clinicians should be incorporating these agents into their treatment algorithms. The other important issue in this breast cancer setting is extended duration of endocrine therapy. Most of the benefit is modest and toxicity is an issue; therefore, extended-duration endocrine therapy should be highly individualized. For triple-negative disease, platinum agents and PARP inhibitors are helping some patients, but immunotherapies and other novel classes of drugs now in development hold the promise of even better outcomes. In HER2-positive early-stage disease, dual HER2 blockade is of modest benefit, and extended treatment with neratinib may be a good option for some high-risk patients.
    MeSH term(s) Antineoplastic Agents, Hormonal/pharmacology ; Antineoplastic Agents, Hormonal/therapeutic use ; Antineoplastic Agents, Immunological/pharmacology ; Antineoplastic Agents, Immunological/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Breast Neoplasms/genetics ; Breast Neoplasms/mortality ; Breast Neoplasms/pathology ; Breast Neoplasms/therapy ; Chemotherapy, Adjuvant/methods ; Chemotherapy, Adjuvant/standards ; Female ; Humans ; Mastectomy/standards ; Medical Oncology/methods ; Medical Oncology/standards ; Neoplasm Staging ; Poly(ADP-ribose) Polymerase Inhibitors/pharmacology ; Poly(ADP-ribose) Polymerase Inhibitors/therapeutic use ; Progression-Free Survival ; Receptor, ErbB-2/antagonists & inhibitors ; Receptor, ErbB-2/metabolism ; Receptors, Estrogen/antagonists & inhibitors ; Receptors, Estrogen/metabolism ; Receptors, Progesterone/antagonists & inhibitors ; Receptors, Progesterone/metabolism ; Societies, Medical/standards ; Time Factors ; United States/epidemiology
    Chemical Substances Antineoplastic Agents, Hormonal ; Antineoplastic Agents, Immunological ; Poly(ADP-ribose) Polymerase Inhibitors ; Receptors, Estrogen ; Receptors, Progesterone ; ERBB2 protein, human (EC 2.7.10.1) ; Receptor, ErbB-2 (EC 2.7.10.1)
    Language English
    Publishing date 2018-05-21
    Publishing country United States
    Document type Journal Article ; Practice Guideline
    ZDB-ID 2250759-0
    ISSN 1540-1413 ; 1540-1405
    ISSN (online) 1540-1413
    ISSN 1540-1405
    DOI 10.6004/jnccn.2018.0043
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6365: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Targeted Therapies in the Treatment of Sarcomas.

    Hoffner, Brianna / Elias, Anthony D / Villalobos, Victor M

    Targeted oncology

    2018  Volume 13, Issue 5, Page(s) 557–565

    Abstract: About 50% of sarcomas have specific pathology-defining molecular alterations including mutations, fusion genes, and gene amplifications. Some of these alterations appear to be oncogenic drivers, and a subset can be utilized as targets for standard or ... ...

    Abstract About 50% of sarcomas have specific pathology-defining molecular alterations including mutations, fusion genes, and gene amplifications. Some of these alterations appear to be oncogenic drivers, and a subset can be utilized as targets for standard or experimental molecularly targeted agents in the clinic. In addition, immunotherapies may have a growing role in the treatment of sarcomas in the future.
    MeSH term(s) Humans ; Immunotherapy/methods ; Sarcoma/drug therapy ; Sarcoma/pathology
    Language English
    Publishing date 2018-08-24
    Publishing country France
    Document type Journal Article ; Review
    ZDB-ID 2222136-0
    ISSN 1776-260X ; 1776-2596
    ISSN (online) 1776-260X
    ISSN 1776-2596
    DOI 10.1007/s11523-018-0583-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article: Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer.

    Li, Zheqi / Spoelstra, Nicole S / Sikora, Matthew J / Sams, Sharon B / Elias, Anthony / Richer, Jennifer K / Lee, Adrian V / Oesterreich, Steffi

    NPJ breast cancer

    2022  Volume 8, Issue 1, Page(s) 62

    Abstract: Both TP53 and ESR1 mutations occur frequently in estrogen receptor positive (ER+) metastatic breast cancers (MBC) and their distinct roles in breast cancer tumorigenesis and progression are well appreciated. Recent clinical studies discovered mutual ... ...

    Abstract Both TP53 and ESR1 mutations occur frequently in estrogen receptor positive (ER+) metastatic breast cancers (MBC) and their distinct roles in breast cancer tumorigenesis and progression are well appreciated. Recent clinical studies discovered mutual exclusivity between TP53 and ESR1 mutations in metastatic breast cancers; however, mechanisms underlying this intriguing clinical observation remain largely understudied and unknown. Here, we explored the interplay between TP53 and ESR1 mutations using publicly available clinical and experimental data sets. We first confirmed the robust mutational exclusivity using six independent cohorts with 1,056 ER+ MBC samples and found that the exclusivity broadly applies to all ER+ breast tumors regardless of their clinical and distinct mutational features. ESR1 mutant tumors do not exhibit differential p53 pathway activity, whereas we identified attenuated ER activity and expression in TP53 mutant tumors, driven by a p53-associated E2 response gene signature. Further, 81% of these p53-associated E2 response genes are either direct targets of wild-type (WT) p53-regulated transactivation or are mutant p53-associated microRNAs, representing bimodal mechanisms of ER suppression. Lastly, we analyzed the very rare cases with co-occurrences of TP53 and ESR1 mutations and found that their simultaneous presence was also associated with reduced ER activity. In addition, tumors with dual mutations showed higher levels of total and PD-L1 positive macrophages. In summary, our study utilized multiple publicly available sources to explore the mechanism underlying the mutual exclusivity between ESR1 and TP53 mutations, providing further insights and testable hypotheses of the molecular interplay between these two pivotal genes in ER+ MBC.
    Language English
    Publishing date 2022-05-10
    Publishing country United States
    Document type Journal Article
    ISSN 2374-4677
    ISSN 2374-4677
    DOI 10.1038/s41523-022-00426-w
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  10. Article ; Online: Identifying the Gate-Opening Mechanism in the Flexible Metal-Organic Framework UTSA-300.

    Acharya, Shree Ram / Elias, Anthony / Tan, Kui / Jensen, Stephanie / Lin, Rui-Biao / Chen, Banglin / Gross, Michael D / Thonhauser, Timo

    Inorganic chemistry

    2022  Volume 61, Issue 12, Page(s) 5025–5032

    Abstract: Atomic-level understanding of the gate-opening phenomenon in flexible porous materials is an important step toward learning how to control, design, and engineer them for applications such as the separation of gases from complex mixtures. Here, we report ... ...

    Abstract Atomic-level understanding of the gate-opening phenomenon in flexible porous materials is an important step toward learning how to control, design, and engineer them for applications such as the separation of gases from complex mixtures. Here, we report such mechanistic insight through an in-depth study of the pressure-induced gate-opening phenomenon in our earlier reported metal-organic framework (MOF) Zn(dps)
    Language English
    Publishing date 2022-03-15
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1484438-2
    ISSN 1520-510X ; 0020-1669
    ISSN (online) 1520-510X
    ISSN 0020-1669
    DOI 10.1021/acs.inorgchem.1c03931
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top